Clinical trial
Prospective microbiological study on patients with non-constipation IBS treated with rifaximin 550 mg tablets.
To determine the effect of Rifaximin 550 mg treatment on the faecal microflora of patients with non-constipation Irritable Bowel Syndrome (non-C IBS).
| Category | Value |
|---|---|
| Study start date | 2011-02-03 |